Clinically relevant molecular subtypes and genomic alteration-independent differentiation in gynecologic carcinosarcoma.


Journal

Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555

Informations de publication

Date de publication:
31 10 2019
Historique:
received: 25 03 2019
accepted: 11 10 2019
entrez: 2 11 2019
pubmed: 2 11 2019
medline: 4 3 2020
Statut: epublish

Résumé

Carcinosarcoma (CS) of the uterus or ovary is a rare, aggressive and biphasic neoplasm composed of carcinoma and sarcoma elements. Previous genomic studies have identified the driver genes and genomic properties associated with CS. However, there is still no molecular subtyping scheme with clinical relevance for this disease. Here, we sequence 109 CS samples, focusing on 596 genes. We identify four molecular subtypes that resemble those observed in endometrial carcinoma: POLE-mutated, microsatellite instability, copy number high, and copy number low subtypes. These molecular subtypes are linked with DNA repair deficiencies, potential therapeutic strategies, and multiple clinicopathological features, including patient outcomes. Multi-regional comparative sequencing reveals genomic alteration-independent CS cell differentiation. Transcriptome and DNA methylome analyses confirm epithelial-mesenchymal transition as a mechanism of sarcoma differentiation. The current study thus provides therapeutic possibilities for CS as well as clues to understanding the molecular histogenic mechanism of its development.

Identifiants

pubmed: 31672974
doi: 10.1038/s41467-019-12985-x
pii: 10.1038/s41467-019-12985-x
pmc: PMC6823358
doi:

Substances chimiques

Poly-ADP-Ribose Binding Proteins 0
RNA, Messenger 0
DNA Polymerase II EC 2.7.7.7
POLE protein, human EC 2.7.7.7

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

4965

Références

Sci Rep. 2017 Apr 4;7(1):641
pubmed: 28377632
Ann Oncol. 2016 Jul;27(7):1257-66
pubmed: 27052653
Nat Commun. 2014 Sep 19;5:5006
pubmed: 25233892
Genome Biol. 2013;14(10):R120
pubmed: 24172663
J Natl Cancer Inst. 2014 Sep 10;106(9):
pubmed: 25214561
Genome Biol. 2010;11(7):R76
pubmed: 20649963
Nat Genet. 2012 Dec;44(12):1310-5
pubmed: 23104009
J Pathol Clin Res. 2015 Apr 09;1(3):173-85
pubmed: 27499902
Genome Res. 2012 Mar;22(3):568-76
pubmed: 22300766
Cancer Res. 1998 Nov 15;58(22):5248-57
pubmed: 9823339
Nucleic Acids Res. 2016 Sep 19;44(16):e131
pubmed: 27270079
Cancer Res. 1997 Dec 1;57(23):5379-85
pubmed: 9393763
Bioinformatics. 2009 Jul 15;25(14):1754-60
pubmed: 19451168
Obstet Gynecol. 2008 Jul;112(1):64-70
pubmed: 18591309
Science. 1989 Nov 17;246(4932):941-2
pubmed: 17812579
Genome Biol. 2011;12(4):R41
pubmed: 21527027
Nat Biotechnol. 2012 May;30(5):413-21
pubmed: 22544022
J Pathol. 1997 Dec;183(4):424-31
pubmed: 9496259
Science. 2014 Oct 10;346(6206):256-9
pubmed: 25301631
Cancer Cell. 2017 Mar 13;31(3):411-423
pubmed: 28292439
Nat Biotechnol. 2013 Mar;31(3):213-9
pubmed: 23396013
Bioinformatics. 2010 Jun 15;26(12):1572-3
pubmed: 20427518
BMC Genomics. 2012 Nov 04;13:591
pubmed: 23442169
Nature. 2011 Jun 29;474(7353):609-15
pubmed: 21720365
Genes Chromosomes Cancer. 2004 Jul;40(3):229-46
pubmed: 15139002
Nature. 2015 May 28;521(7553):489-94
pubmed: 26017449
Genome Res. 2010 Sep;20(9):1297-303
pubmed: 20644199
Gynecol Oncol. 2015 Jun;137(3):581-8
pubmed: 25805398
Clin Cancer Res. 2016 Feb 1;22(3):609-20
pubmed: 26420858
Nat Rev Cancer. 2015 Nov;15(11):668-79
pubmed: 26493647
Mod Pathol. 2011 Oct;24(10):1368-79
pubmed: 21572397
Nat Rev Cancer. 2016 Sep;16(9):599-612
pubmed: 27515922
Mutat Res. 2005 Sep 4;577(1-2):275-83
pubmed: 15922366
Cancer Control. 2016 Jan;23(1):61-6
pubmed: 27009459
Nat Genet. 2011 May;43(5):491-8
pubmed: 21478889
Genet Med. 2015 May;17(5):405-24
pubmed: 25741868
Cancer Res. 1995 Dec 1;55(23):5664-9
pubmed: 7585651
Cancer Res. 2000 Jan 1;60(1):114-20
pubmed: 10646862
BMC Bioinformatics. 2011 Aug 04;12:323
pubmed: 21816040
Bioinformatics. 2011 Oct 1;27(19):2648-54
pubmed: 21828086
Cancer Res. 2014 May 1;74(9):2465-75
pubmed: 24788099
J Natl Compr Canc Netw. 2009 May;7(5):550-6; quiz 557
pubmed: 19460280
Am J Surg Pathol. 1996 Mar;20(3):277-85
pubmed: 8772780
Int J Gynaecol Obstet. 2009 May;105(2):103-4
pubmed: 19367689
Clin Cancer Res. 2013 Jan 1;19(1):279-90
pubmed: 23091115
Int J Gynecol Pathol. 2014 Sep;33(5):483-91
pubmed: 25083964
J Reprod Med. 2013 Jul-Aug;58(7-8):297-304
pubmed: 23947079
Cancer. 2018 Jan 1;124(1):65-73
pubmed: 28940304
J Natl Cancer Inst. 2014 Dec 12;107(1):402
pubmed: 25505230
Blood. 2013 Nov 21;122(22):3616-27; quiz 3699
pubmed: 24030381
Curr Protoc Bioinformatics. 2013;43:11.10.1-11.10.33
pubmed: 25431634
Bioinformatics. 2013 Sep 15;29(18):2238-44
pubmed: 23884480
Proc Natl Acad Sci U S A. 2016 Oct 25;113(43):12238-12243
pubmed: 27791010
Nat Methods. 2013 Nov;10(11):1081-2
pubmed: 24037244
Genes Chromosomes Cancer. 2012 Mar;51(3):229-39
pubmed: 22072501
EMBO Mol Med. 2014 Sep 11;6(10):1279-93
pubmed: 25214461
J Clin Pathol. 2002 May;55(5):321-5
pubmed: 11986333
Int J Gynecol Cancer. 2014 Nov;24(9 Suppl 3):S55-60
pubmed: 25341582
Am J Clin Pathol. 2004 Oct;122(4):546-51
pubmed: 15487452
Nature. 2013 May 2;497(7447):67-73
pubmed: 23636398
JCO Precis Oncol. 2018 Nov;2:1-4
pubmed: 35135167
J Clin Oncol. 2016 Sep 1;34(25):3062-8
pubmed: 27325856
J Pathol. 2012 Sep;228(1):20-30
pubmed: 22653804
Mod Pathol. 2006 Oct;19(10):1333-8
pubmed: 16810312

Auteurs

Osamu Gotoh (O)

Project for Development of Innovative Research on Cancer Therapeutics, Cancer Precision Medicine Center, Japanese Foundation for Cancer Research, 3-8-31 Ariake, Koto-ku, Tokyo, Japan.

Yuko Sugiyama (Y)

Department of Gynecology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, 3-8-31 Ariake, Koto-ku, Tokyo, Japan.

Yutaka Takazawa (Y)

Department of Pathology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, 3-8-31 Ariake, Koto-ku, Tokyo, Japan.

Kazuyoshi Kato (K)

Department of Gynecology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, 3-8-31 Ariake, Koto-ku, Tokyo, Japan.

Norio Tanaka (N)

Project for Development of Innovative Research on Cancer Therapeutics, Cancer Precision Medicine Center, Japanese Foundation for Cancer Research, 3-8-31 Ariake, Koto-ku, Tokyo, Japan.

Kohei Omatsu (K)

Department of Gynecology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, 3-8-31 Ariake, Koto-ku, Tokyo, Japan.

Nobuhiro Takeshima (N)

Department of Gynecology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, 3-8-31 Ariake, Koto-ku, Tokyo, Japan.

Hidetaka Nomura (H)

Department of Gynecology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, 3-8-31 Ariake, Koto-ku, Tokyo, Japan.

Kosei Hasegawa (K)

Department of Gynecologic Oncology, Saitama Medical University International Medical Center, 1397-1 Yamane, Hidaka-shi, Saitama, Japan.

Keiichi Fujiwara (K)

Department of Gynecologic Oncology, Saitama Medical University International Medical Center, 1397-1 Yamane, Hidaka-shi, Saitama, Japan.

Mana Taki (M)

Department of Gynecologic Oncology, Kyoto University Hospital, 54 Kawaharacho, Shogoin, Sakyo-ku, Kyoto, Japan.

Noriomi Matsumura (N)

Department of Gynecologic Oncology, Kyoto University Hospital, 54 Kawaharacho, Shogoin, Sakyo-ku, Kyoto, Japan.

Tetsuo Noda (T)

Project for Development of Innovative Research on Cancer Therapeutics, Cancer Precision Medicine Center, Japanese Foundation for Cancer Research, 3-8-31 Ariake, Koto-ku, Tokyo, Japan.

Seiichi Mori (S)

Project for Development of Innovative Research on Cancer Therapeutics, Cancer Precision Medicine Center, Japanese Foundation for Cancer Research, 3-8-31 Ariake, Koto-ku, Tokyo, Japan. seiichi.mori@jfcr.or.jp.

Articles similaires

Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH